Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice

DOI: 10.1016/j.ijcard.2016.04.098
International Journal of Cardiology, 2016, 216, 85-91.

#	Paper	IF	Citations
26	Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. *Handbook of Experimental Pharmacology*, **2017**, 243, 225-247	3.2	49
25	Pharmacology of heart failure: From basic science to novel therapies. *Pharmacology & Therapeutics*, **2016**, 166, 136-49	13.9	12
24	Heart Failure. *Handbook of Experimental Pharmacology*, **2017**,	3.2	4
23	A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases. *Biomedicine and Pharmacotherapy*, **2017**, 94, 541-556	7.5	25
22	Gallic acid attenuates pulmonary fibrosis in a mouse model of transverse aortic contraction-induced heart failure. *Vascular Pharmacology*, **2017**, 99, 74-82	5.9	9
21	Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension. *Pulmonary Circulation*, **2018**, 8, 2045893217746111	2.7	4
20	Soluble Guanylate Cyclase Stimulators and Activators. *Handbook of Experimental Pharmacology*, **2021**, 264, 355-394	3.2	51
19	Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. *BioMed Research International*, **2018**, 2018, 3293584	3	17
18	Pathophysiological Mapping of Experimental Heart Failure: Left and Right Ventricular Remodeling in Transverse Aortic Constriction Is Temporally, Kinetically and Structurally Distinct. *Frontiers in Physiology*, **2018**, 9, 472	4.6	16
17	Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth. *PLoS ONE*, **2018**, 13, e0199927	3.7	13
16	Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases. *Nitric Oxide - Biology and Chemistry*, **2018**, 77, 88-95	5	22
15	Emerging pharmacotherapies in cystic fibrosis. *Expert Review of Respiratory Medicine*, **2018**, 12, 843-855	3.8	6
14	Pulmonary vascular mechanical consequences of ischemic heart failure and implications for right ventricular function. *American Journal of Physiology - Heart and Circulatory Physiology*, **2019**, 316, H1167-H1177	5.2	13
13	Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling. *British Journal of Pharmacology*, **2020**,	8.6	5
12	Stimulation of soluble guanylate cyclase improves donor organ function in rat heart transplantation. *Scientific Reports*, **2020**, 10, 5358	4.9	3
11	FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction. *Basic Research in Cardiology*, **2020**, 115, 17	11.8	14
10	Effect of sildenafil on right ventricular performance in an experimental large-animal model of postcapillary pulmonary hypertension. *Translational Research*, **2021**, 228, 64-75	11	1

9	Clinical Significance of Guanylate Cyclase Stimulator, Riociguat, on Right Ventricular Functional Improvement in Patients with Pulmonary Hypertension. *Cardiology*, **2021**, 146, 130-136	1.6	3
8	Experimental Models. **2021**, 27-52		
7	Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. *Nature Reviews Cardiology*, **2021**, 18, 479-498	14.8	20
6	Animal models of pulmonary hypertension due to left heart disease.. *Animal Models and Experimental Medicine*, **2022**,	4.2	0
5	Riociguat attenuates left ventricular proteome and microRNA profile changes after experimental aortic stenosis in mice. *British Journal of Pharmacology*,	8.6	1
4	Treatment of myocardial interstitial fibrosis in pathological myocardial hypertrophy. 13,		0
3	Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. **2022**, 31, 220061		0
2	A Comprehensive Assessment of Right Ventricular Function in Chronic Thromboembolic Pulmonary Hypertension. **2023**, 12, 47		0
1	Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model. **2023**, 24, 2391		0